Advertisement

Topics

Switching to Tresiba® is highly cost-effective and cost-saving in a real-world setting

05:00 EST 7 Nov 2017 | PharmaNews.EU

Novo NordiskA new analysis of real-world data has shown that switching to Tresiba® (insulin degludec) is highly cost-effective and cost-saving for the treatment of type 1 and type 2 diabetes, respectively.(1) The analysis was presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2017) 20th Annual European Congress.

Original Article: Switching to Tresiba® is highly cost-effective and cost-saving in a real-world setting

NEXT ARTICLE

More From BioPortfolio on "Switching to Tresiba® is highly cost-effective and cost-saving in a real-world setting"

Advertisement
Quick Search
Advertisement
Advertisement